← FDA DRUG APPROVALS

FDA ANDA · ANDA080235

VASOCON

Sponsor: NOVARTIS

APPLICATION
ANDA080235
TYPE
ANDA
ORIGINAL APPROVAL
1971-06-07
LATEST ACTION
2001-04-19
ROUTE
OPHTHALMIC
DOSAGE FORM
SOLUTION/DROPS
MARKETING STATUS
Discontinued

Products

VASOCONDiscontinued
NAPHAZOLINE HYDROCHLORIDE 0.1% · SOLUTION/DROPS · OPHTHALMIC

Approval history

2001-04-19Manufacturing (CMC) · Supplement 19AP
1995-07-07Manufacturing (CMC) · Supplement 13AP
1994-10-07Manufacturing (CMC) · Supplement 14AP
1994-06-10Manufacturing (CMC) · Supplement 15AP
1992-10-08Manufacturing (CMC) · Supplement 12AP
1991-01-16Labeling · Supplement 8AP
1986-08-11Manufacturing (CMC) · Supplement 7AP
1983-03-24Manufacturing (CMC) · Supplement 5AP
1982-07-28Manufacturing (CMC) · Supplement 3AP
1982-07-28Manufacturing (CMC) · Supplement 4AP
1971-06-07OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →